Pharmacy Drugs
Recent Posts
- EPIX Pharmaceuticals Announces FDA Approval Of A Physician-Sponsored IND For Fourth 6-month Open Label Extension Of PRX-03140 For Alzheimer’s Disease
- Miriam Hospital Researcher Receives More Than $12 Million To Study Weight Control
- Novel HIV Drug To Be Studied In Cell Cultures And Patients
- ISCTM Meeting Discusses Clinical And Regulatory Aspects Of Using Adaptive Designs In Clinical Trials For Central Nervous System Drug Approvals
- Evaluation Of The Cost Effectiveness Of Implantable Blood Pressure Device
Random Posts
- FDA Issues Warning for Defective AEDs
- Trial Of Device That Reshapes Enlarged, Leaky Heart Valve Shows Intriguing Early Results
- Rise In New Cases Of Alzheimer's And Dementia, Even In The 'Oldest Old'
- Human Trials Commence Next Year For The First Genetically-Engineered Malaria Vaccine
- Abbott Seeks FDA Approval Of New Dosage Strengths Of SIMCOR(R) (niacin Extended-release/simvastatin)
- New Device Gauges Breast Tumor Margins During Surgery
- Policy Recommendations For Improving Medication Adherence
- FDA Reviewing Safety Data for Insulin Glargine
- Diet High In Methionine Could Increase Risk Of Alzheimer's
- Old Gout Drug Gets New Indication
Pharmacies Urged To Register From 1 - 31 July 2009 To Receive Early-bird Payment
Posted by: admin in Pharmacy Drugs on July 12th, 2009
Community pharmacies are urged to register to participate in Phase 2 of the Dose Administration Aids
(DAA) and Patient Medication Profile (PMP) programs.
Pharmacies registering from 1 to 31 July 2009 will be eligible for the full incentive payment of $2,250 for
DAA and $1,250 for PMP (+GST). While registrations will still be accepted after July, a lesser incentive
payment will apply.
“We need as many pharmacies as possible to participate in Phase 2 of these programs to ensure the ongoing
and sustainable delivery of these important services,” said Mr Kos Sclavos, .National President of the
Pharmacy Guild of Australia.
In response to feedback from community pharmacy, the DAA and PMP programs, managed by the
Pharmacy Guild of Australia, have been reviewed and revamped to make participation in them easier and
systems more user-friendly. The amount of time and data required has been reduced, and the payment
deadlines have been simplified.
“DAA and PMP services offer clear benefits to patients and the wider community. Patients have better
medication management, and better continuity of care. The community have fewer hospitalizations
associated with medicine misadventure and delayed admissions to aged care services,” said Mr Warwick
Plunkett, National President of the Pharmaceutical Society of Australia.
Medication misadventure is estimated to cost the health sector $380 million a year (Source: ‘Improving
Medication Safety’ by the Australian Council for Safety and Quality in Healthcare, 2002).
The DAA program allows pharmacist to organise patients’ medicines into weekly blister packs. The PMP
allows pharmacists to produce a comprehensive profile of the patient’s medicines, including information
about instructions for use, appearance and generic substitution availability.
The DAA and PMP Programs are funded under the Better Community Health Initiative of the Fourth
Community Pharmacy Agreement by the Australian Government Department of Health and Ageing.
In mid-June, all pharmacies will receive a new Pharmacy Readiness Kit with information and new PMP
promotional materials to support their participation.
For more information visit the Guild website at http://www.guild.org.au
Source
Pharmaceutical Society of Australia